Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 19/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3057651 | 0.88 | CCR1 (0.64) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3063748 | 0.87 | CCR1 (0.63) | CCR1CYP2C19KCNH2 | |
| SCHEMBL13362075 | 0.87 | KMT2A (0.58) | CCR1KMT2ATDP1 | |
| SCHEMBL3780578 | 0.85 | CCR1 (0.61) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3772008 | 0.83 | CCR1 (0.59) | CCR1CYP2C19KCNH2 | |
| SCHEMBL14180542 | 0.82 | L3MBTL1 (0.54) | CCR1KMT2ATDP1CYP2C19 | |
| SCHEMBL12765632 | 0.82 | CCR1 (0.65) | CCR1CYP2C19KCNH2 | |
| SCHEMBL1639577 | 0.82 | CCR1 (0.69) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3773688 | 0.82 | CCR1 (0.58) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3767770 | 0.82 | CCR1 (0.58) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1931348-A4 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1931348-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | CCR1 1/4885KMT2A 4350/4885TDP1 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.